On June 4, 2025, Pacific Biosciences announced stockholder approval for an amendment to its 2020 Equity Incentive Plan, allowing for an additional 23 million shares to be reserved for issuance. The annual meeting also saw the election of directors and ratification of Ernst & Young as auditors.